Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBI-RESP
- Development stage
- Preclinical
- Lead developer
- Replicate Bioscience
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RBI-RESP is a multivalent self-replicating RNA (srRNA) vaccine candidate being developed by Replicate Bioscience for the prevention of infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV). Utilizing Replicate's proprietary srRNA platform, the vaccine encodes multiple antigens from these three respiratory pathogens. The srRNA technology includes virally-derived genetic components that enable controlled self-amplification of the RNA within host cells, leading to sustained and high-level protein expression. This approach is designed to elicit robust and durable immune responses at significantly lower doses than conventional mRNA vaccines, potentially offering a more effective and scalable solution for complex respiratory viral threats.
- Other names
- RBI-RESP vaccine
02
Targets
hMPV (Human metapneumovirus)
Beyond the preview
Go deeper on RBI-RESP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBI-RESP.